Phase II Study of Bevacizumab Plus CHOP-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL)
Bevacizumab administered at 15 mg/kg on day 1 of each of 6 cycles
Rituximab administered 375 mg/m2 on day 3 of each of 6 cycles (with usual premedications)
Standard CHOP chemotherapy administered on day 3 every 21 days (full dose) for 6 cycles of
treatment
Once completed six cycles of therapy (~18 weeks), patients will be evaluated every 3 months
for the first year post treatment, then every 6 months until disease progression or death
for years 2 through 5 post treatment. Patients who have disease progression will be
contacted every 6 months until death to assess for survival status.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
effect of bevacizumab + CHOP-rituximab on untreated mantle cell lymphoma
duration of study
No
John P Leonard, MD
Principal Investigator
Weill Medical College of Cornell University
United States: Food and Drug Administration
0604008463
NCT00401817
November 2007
July 2011
Name | Location |
---|---|
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Weill Medical College of Cornell University | New York, New York 10021 |